Analyst Price Targets — MBX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 10, 2026 2:12 pm | — | Truist Financial | $88.00 | $65.87 | TheFly | MBX Biosciences price target raised to $88 from $70 at Truist |
| August 7, 2026 10:16 am | — | Barclays | $88.00 | $67.11 | TheFly | MBX Biosciences price target raised to $88 from $70 at Barclays |
| July 23, 2026 1:37 pm | Michael Yee | UBS | $90.00 | $61.84 | TheFly | MBX Biosciences price target raised to $90 from $60 at UBS |
| May 12, 2026 12:00 pm | — | Stifel Nicolaus | $56.00 | $38.99 | TheFly | MBX Biosciences price target raised to $56 from $50 at Stifel |
| May 12, 2026 9:57 am | — | Barclays | $70.00 | $40.08 | TheFly | MBX Biosciences price target raised to $70 from $66 at Barclays |
| May 11, 2026 1:51 pm | Srikripa Devarakonda | Truist Financial | $70.00 | $43.79 | TheFly | MBX Biosciences price target raised to $70 from $50 at Truist |
| March 9, 2026 12:57 pm | Srikripa Devarakonda | Truist Financial | $50.00 | $28.78 | StreetInsider | Truist Securities Reiterates Buy Rating on MBX Biosciences Inc (MBX) |
| January 27, 2026 9:26 pm | — | Barclays | $66.00 | $36.07 | TheFly | MBX Biosciences initiated with an Overweight at Barclays |
| January 16, 2026 11:33 am | Seamus Fernandez | Guggenheim | $88.00 | $40.91 | StreetInsider | MBX Biosciences Inc (MBX) PT Raised to $88 at Guggenheim |
| January 7, 2026 5:44 am | Michael Yee | UBS | $60.00 | $28.70 | StreetInsider | UBS Starts MBX Biosciences Inc (MBX) at Buy |
Latest News for MBX
Pivotal Phase 3 oPTimize trial design builds on positive Phase 2 Avail™ results and durable one-year clinical benefit
Q3 Revenues of $4.1 million and Controlled Net Loss MISSISSAUGA, ON / ACCESS Newswire / August 13, 2026 / Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF, Microbix® ), a life sciences innovator, manufacturer, and exporter, reports results for its third quarter and nine months of fiscal 2026 ended June 30, 2026 ("Q3" and "YTD"). Results for Q3 and YTD continue to demonstrate the results of the Company's continuing…
MBX Biosciences, Inc. (NASDAQ: MBX - Get Free Report) shares hit a new 52-week high during mid-day trading on Thursday after Mizuho raised their price target on the stock from $57.00 to $91.00. Mizuho currently has an outperform rating on the stock. MBX Biosciences traded as high as $66.66 and last traded at $66.46, with a
MBX Biosciences, Inc. (NASDAQ: MBX - Get Free Report)'s share price hit a new 52-week high during trading on Friday. The company traded as high as $66.66 and last traded at $61.10, with a volume of 107404 shares trading hands. The stock had previously closed at $63.57. Analyst Ratings Changes A number of analysts have
MBX Biosciences (NASDAQ: MBX - Get Free Report) and Lakewood-Amedex Biotherapeutics (NASDAQ: LABT - Get Free Report) are both manufacturing companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, dividends and valuation. Valuation and Earnings This table compares MBX Biosciences
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for MBX.
U.S. House Trading
No House trades found for MBX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.